Benzamide, 3-methoxy-N-[4-(4-methoxyphenyl)-2-thiazolyl]-4-[2-(4-morpholinyl)-2-oxoethoxy]- manufacturers
- SBI-477
-
- $155.00
-
2026-05-11
- CAS:781628-99-7
- Purity: 99.30%
- Supply Ability: 10g
- SBI-477
-
- $155.00
-
2026-05-11
- CAS:781628-99-7
- Purity: 99.30%
- Supply Ability: 10g
|
| | Benzamide, 3-methoxy-N-[4-(4-methoxyphenyl)-2-thiazolyl]-4-[2-(4-morpholinyl)-2-oxoethoxy]- Basic information |
| | Benzamide, 3-methoxy-N-[4-(4-methoxyphenyl)-2-thiazolyl]-4-[2-(4-morpholinyl)-2-oxoethoxy]- Chemical Properties |
| density | 1.331±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: 65 mg/mL (134.43 mM) | | form | Solid | | pka | 7.14±0.50(Predicted) | | color | Light yellow to yellow |
| | Benzamide, 3-methoxy-N-[4-(4-methoxyphenyl)-2-thiazolyl]-4-[2-(4-morpholinyl)-2-oxoethoxy]- Usage And Synthesis |
| Uses | SBI-477 is a chemical probe stimulated insulin signaling by deactivating the transcription factor MondoA, leading to reduced expression of the insulin pathway suppressors thioredoxin-interacting protein (TXNIP) and arrestin domain–containing 4 (ARRDC4). SBI-477 coordinately inhibits triacylglyceride (TAG) synthesis and enhances basal glucose uptake in human skeletal myocytes[1]. | | References | [1] Ahn B, et al. MondoA coordinately regulates skeletal myocyte lipid homeostasis and insulin signaling. J Clin Invest. 2016 Sep 1;126(9):3567-79. DOI:10.1172/JCI87382 |
| | Benzamide, 3-methoxy-N-[4-(4-methoxyphenyl)-2-thiazolyl]-4-[2-(4-morpholinyl)-2-oxoethoxy]- Preparation Products And Raw materials |
|